Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

Shepherd, James, Barter, Philip, Carmena, Rafael, Deedwania, Prakash, Fruchart, Jean-Charles, Haffner, Steven, Hsia, Judith, Breazna, Andrei +4 more·2006·Diabetes Care
DOI 10.2337/dc05-2465

Cited by (525)

Items 401–500 of 525

  1. Efficacy of simvastatin therapy in attainment of LDL-C and TG goal levels in patients with type 2 diabetic dyslipidemia
    Adrian Sandra Dobs, Michael J. Miller, Paul T. DeLucca, Karen E. Ramsey, Andrew M. Tershakovec, Wendy Horn · 2007 · Journal of clinical lipidology
  2. Pathophysiological Links Between Diabetes and Cardiovascular Diseases: at the Biochemical and Molecular Levels
    Mirajul Islam, Yearul Kabir · 2022 · Frontiers in cardiovascular drug discovery
  3. Combination Therapy for Dyslipidemia
    Michael H. Davidson · 2009 · Elsevier eBooks
  4. Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes
    Martial G. Bourassa, Colin Berry · 2008 · Current Atherosclerosis Reports
  5. Lipid goals in metabolic syndrome and diabetes
    Helen Martina Colhoun · 2007 · Current Atherosclerosis Reports
  6. Lipid management in Type 2 diabetes: the case for combination therapy?
    Christoph H. Saely, Veronika Drexel, Alexander Vonbank, Heinz Drexel · 2011 · Therapy
  7. Implementation of the American Diabetes Association's Standards of Medical Care post-Medicare Part D: The case of statin utilization in the elderly with diabetes
    Kevin Lu, Minghui Li, Whitney D. Maxwell, Richard Schulz · 2015 · Research in Social and Administrative Pharmacy
  8. Europejskie wytyczne dotyczace zapobiegania chorobom serca i naczyń w praktyce klinicznej na 2012 rok
    Joep Perk, Guy De Backer, H. Gohlke, Ian M Graham, Željko Reiner, W. M. Monique Verschuren, Christian Albus, Pascale Benlian, Gudrun Boysen, Renata Cífková et al. · 2012 · Ghent University Academic Bibliography (Ghent University)
  9. Dyslipidemia and Diabetes
    Ioanna Gouni‐Berthold, David Betteridge, Wilhelm Krone · 2007 · CRC Press eBooks
  10. Cardiovascular disease risk reduction in diabetes through conventional and natural approaches
    William M. Schultz, Elliot N. Mahlof, Devinder Singh Dhindsa, Tina Varghese, Robert E. Heinl, Hannah C. Cai, Pratik B. Sandesara, Danny J. Eapen, Laurence S. Sperling · 2017 · Cardiovascular Endocrinology
  11. Effect of Lipid-Testing Interval on Stoke Risk among Newly Diagnosed Dyslipidemia Patients Initiated on Statins
    Ahryoung Ko, Seulggie Choi, Jooyoung Chang, Sang Min Park · 2019 · Journal of Clinical Medicine
  12. Percutaneous Coronary Intervention Rates and Associated Independent Predictors for Progression of Nontarget Lesions in Patients With Diabetes Mellitus After Drug-Eluting Stent Implantation
    Le Wang, Yujie Zhou, Pingan Peng, Xiaohan Xu, Shiwei Yang, Wei Liu, Hongya Han, Dean Jia, Jianlong Wang, Qingwei Ji et al. · 2015 · Angiology
  13. Efficacy, Safety and Protective Effects of Lipid Lowering Drugs in Patients with Diabetes
    Yosra Htira, Manel Dridi, Zohra Hadj Ali, Nabil Trabelsi, F. Ben Mami · 2022 · European Journal of Medical and Health Sciences
  14. Diabetic Dyslipidemia
    Ronald A. Codario · 2010 · Humana Press eBooks
  15. PowerAI-Diabetes: Review of glycemic and lipid variability to predict cardiovascular events in Chinese diabetic population
    Sharen Lee, Tong Liu, Cheuk To Chung, Johannes Reinhold, Vassilios S. Vassiliou, Gary Tse · 2024 · npj Metabolic Health and Disease
  16. Glycemic and Cholesterol Control Versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study
    Lizheng Shi, Xin Ye, Mei Lü, Eric Qiong Wu, Hari Sharma, Darren Thomason, Mengxi Zhang, Yao Wang, Vivian Andrew Fonseca · 2015 · Diabetes Therapy
  17. Anti-PCSK9 antibodies — beneficial or inducers of diabetes?
    Rutger Verbeek, G. Kees Hovingh · 2017 · Nature Reviews Endocrinology
  18. Rational therapy of mixed dyslipidaemia in a patient with diabetes
    Charles A. Reasner · 2007 · The British Journal of Diabetes
  19. Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?
    Michel Farnier · 2018 · Annals of Translational Medicine
  20. Management of atherogenic dyslipidemia according to current treatment guidelines: DESPEGA study in real clinical practice
    Jesús Millán Núñez-Cortés, Patricia Rodríguez‐Fortúnez, Malena Melogno Klinkas, Marta Rodríguez de Miguel, Susana Aceituno, Maria Luisa Orera Peña · 2019 · Drugs & Therapy Perspectives
  21. Contemporary treatment strategies for Type 2 diabetes-related macrovascular disease
    Andrew MN Walker, Richard M. Cubbon, Mark T. Kearney · 2014 · Expert Review of Endocrinology & Metabolism
  22. A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in diabetic patients without prior cardiovascular disease
    JoAnne Micale Foody, Amie T. Joyce, Barrett W. Jeffers, Larry Z. Liu, Joshua S. Benner · 2008 · Diabetes Research and Clinical Practice
  23. Targeting High-Density Lipoprotein and Triglycerides in Statin-Treated Patients with Diabetes
    Denise E. Bonds · 2011 · Current Cardiovascular Risk Reports
  24. L’intérêt démontré des statines chez les patients diabétiques de type 2
    Bruno L Vergès · 2010 · Médecine des Maladies Métaboliques
  25. Diabetes and Heart Disease
    Burton E. Sobel · 2015 · Cardiovascular medicine
  26. Treatment of dyslipidemia in patients with type 2
    Krishnaswami Vijayaraghavan · 2010
  27. Avant-propos Ars longa… iudicium difficile. L’exemple des recommandations dans les dyslipidémies du diabétique
    Louis Monnier, C Colette, Abdelilah El Azrak, Driss Rochd, N. Essekkat, Anggi Maysa Noviana Bakri · 2018 · Médecine des Maladies Métaboliques
  28. Stroke and Diabetes Mellitus
    Boris Mankovsky · 2009 · Humana Press eBooks
  29. Principles of Diabetes Care and Lifestyle Modification
    Min Kyong Moon · 2021 · Stroke revisited
  30. Study of High Density Lipoprotein Cholesterol among Patients with Acute Coronary Syndrome in Sohag University Hospital
    2015 · Journal of Cardiology & Current Research
  31. Endothelial Dysfunction in Type 2 Diabetes with an Update on New Interventions
    Natalie C. Ward, Wann Jia Loh, Gerald Francis Watts · 2023 · Contemporary diabetes
  32. The role of PPAR-α agonists in the prevention of CVD in diabetes
    Marja‐Riitta Taskinen · 2007 · Current Diabetes Reports
  33. Risk Factors Management in Diabetic Patients
    Sang Yong Kim · 2019 · Journal of Korean Diabetes
  34. Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes
    Suzanne V. Arnold, KENSEY L. GOSCH, Nathan D. Wong, Vittal Hejjaji, Abhinav Goyal, Lawrence A. Leiter, Mikhail Kosiborod · 2020 · Endocrinology Diabetes & Metabolism
  35. Dyslipidémie
    G.B. John Mancini, Robert Alexander Hegele, Lawrence A. Leiter · 2013 · Canadian Journal of Diabetes
  36. The 2021 ESC guidelines on cardiovascular prevention: Whether the ends justify the means
    Claudio Cimminiello, Charalambos Vlachopulos, Marco De Carlo · 2021 · European Journal of Internal Medicine
  37. Dyslipidaemia, glucose intolerance and cardiovascular disease mortality and morbidity in Europeans and Asians
    Lei Zhang · 2010 · Työväentutkimus Vuosikirja
  38. Risque cardiovasculaire résiduel du patient diabétique de type 2
    Bruno L Vergès · 2010 · Médecine des Maladies Métaboliques
  39. Management of Diabetic Dyslipidaemia
    D. J. Betteridge · 2007 · Springer eBooks
  40. Fenofibric Acid: Safety and Efficacy in the Treatment of Dyslipidemia, Hypertriglyceridemia and Hyperlipidemia
    Susan Marie Schima · 2011 · Clinical Medicine Reviews in Vascular Health
  41. The ACCORD LIPID Trial
    Nicola I. Abate, Manisha Chandalia · 2010 · Metabolic Syndrome and Related Disorders
  42. Do People With Diabetes Need Statins?
    John Raymond White · 2008 · The Science of Diabetes Self-Management and Care
  43. Diabetes in the coronary care unit
    Timothy M. E. Davis · 2011 · Elsevier eBooks
  44. Diabetic Considerations in Cerebrovascular Disease
    Christine J. Chung, Sharif H. Ellozy, Michael L. Marin, Peter L. Faries · 2012 · Humana Press eBooks
  45. Fettstoffwechsel und Hypertonie bei Diabetes
    Heinz Drexel, S. Jacob, Klaus Georg Parhofer, Christoph Säly, Hendrik Schatz, Alexander Vonbank · 2014 · Springer eBooks
  46. Diabetes Mellitus Prevention and Treatment
    Andrea Vegh Dunn, Kavita Nyalakonda · 2013 · Humana Press eBooks
  47. Metabolic Regulation of Endothelial Dysfunction and Cardiovascular Risk
    Joanna Mary Young · 2012 · Otago University Research Archive (University of Otago)
  48. Estrès del reticle endoplasmàtic, inflamació i resistència a la insulina en cèl•lules musculars esquelètiques
    Laia Salvadó Serra · 2014 · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
  49. Bedeutung der Lipidtherapie bei Diabetes
    Christoph H. Saely, Heinz Drexel · 2010 · Wiener Medizinische Wochenschrift
  50. Does Treating Hyperlipidaemia with Medication Prevent Complications?
    Helen Martina Colhoun · 2010
  51. Dyslipidemia and Its Management in Type 2 Diabetes
    D. J. Betteridge · 2014 · Wiley eBooks
  52. Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ) as a Potential Therapeutic Target for Dyslipidemia
    Emma Barroso, Luca Serrano-Marco, Laia Salvad, Xavier Palomer, Manuel Vzquez-Carrer · 2012 · InTech eBooks
  53. Insulin resistance and adipose tissue in the development of vascular diseases in high-risk patients
    Petra M. Gorter · 2008 · Utrecht University Repository (Utrecht University)
  54. En pacientes de alto riesgo, mientras más bajo el colesterol de baja densidad (c-LDL), mejor: ¿Qué tan bajo y cuál es su grado de recomendación y nivel de evidencia?
    Alonso Merchán · 2008 · DOAJ (DOAJ: Directory of Open Access Journals)
  55. Estudio de las características metabólicas, hormonales e inmunoinflamatorias de mujeres con síndrome de ovarios poliquísticos con o sin obesidad. Análisis del impacto del tratamiento con atorvastatina
    Jorly Mejía-Montilla · 2012 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
  56. Tratamento com estatina no diabético tipo 2
    Joana Amorim · 2013 · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo
  57. La prévention primaire par les statines du risque cardiovasculaire des diabétiques : un mauvais procès en place publique
    André Grimaldi · 2013 · Archives des Maladies du Coeur et des Vaisseaux - Pratique
  58. Risikofaktoren für Schlaganfall und ihre therapeutische Beeinflussung
    Burkhard Alber, Robert Müller, Gerhard F. Hamann · 2015 · DNP - Der Neurologe und Psychiater
  59. Infradiagnosed complications of chronic diabetes mellitus: The value of systematic review in a single visit
    Mercè Fernández-Miró, Cristina Colom, Ariadna Lloveras, Gemma Llauradó, Juan José Chillarón · 2012 · Endocrinología y Nutrición (English Edition)
  60. Maladie coronaire du diabétique
    Jean-Jacques Monsuez, Soumaya Ikhefoulma, Abdel Mahiou, Thierry Landre · 2010 · Archives des Maladies du Coeur et des Vaisseaux - Pratique
  61. Tratamiento farmacológico de la dislipemia en la diabetes mellitus tipo 2
    J.T. Real, Rafael Carmena · 2008 · Endocrinología y Nutrición
  62. Review: The role of fenofibrate in reducing cardiovascular risk in type 2 diabetes
    Juan Pedro‐Botet · 2008 · The British Journal of Diabetes
  63. Observational study of ezetimibe discontinuation in primary care practices in the UK
    Gillian C. Hall, Vian Amber, Chris O’Regan, Kevin Jameson · 2013 · Current Medical Research and Opinion
  64. Study of High Density Lipoprotein Cholesterol among Patients with Acute Coronary Syndrome in Sohag niversity Hospital
    Nagwa Thabet, Hassan Ahmad Hassanin, Yasser Kamal · 2015 · Journal of Cardiology & Current Research
  65. The Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
    B. V. Howard, M.J. Roman, Richard B. Devereux · 2008 · Journal of Vascular Surgery
  66. Title: Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline Short Title: Guidelines for Patients at Metabolic Risk
    James L. Rosenzweig, Ele Ferrannini, Scott M. Grundy, Steven M. Haffner, Robert J. Heine, Edward S. Horton, Ryuzo Kawamori · 2008
  67. Therapeutic Class Overview HMG CoA Reductase Inhibitors
    Lescol Xl · 2012
  68. Interdisciplinary Council on Quali Blood Pressure Research, Council on Peripheral Vascular Disease, and Cardiovascular Nursing, Council on Epidemiology and Prevention, Council for High and on behalf of the American Heart Association Stroke Council, Council on
    James Frederick Meschia, Wesley S. Moore, Thomas A. Pearson, Robert G. Hart, Judith A. Hinchey, Virginia J. Howard, Edward C. Jauch, Seemant Chaturvedi, Mark A. Creager, Antonio Culebras et al. · 2010
  69. HEART FAILURE AND DIABETES MELLITUS: WHO SHOULD BE IN CHARGE ?
    Rodica Dan, Lucian Petrescu, Romulus Zorin Timar, Stefan Iosif Dragulescu · 2009
  70. Endothelial Dysfunction and Dyslipidemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy
    Sandra J. Hamilton, Gerald Francis Watts · 2013 · Contemporary diabetes
  71. Estudio de las características metabólicas, hormonales e inmunoinflamatorias de mujeres con síndrome de ovarios poliquísticos con o sin obesidad. Análisis del impacto del tratamiento con atorvastatina
    Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
  72. Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica (versión 2012) Quinto Grupo de Trabajo de la Sociedad Europea de Cardiología y otras Sociedades sobre la Prevención de la Enfermedad Cardiovascular en la Práctica Clínica (constituido por representantes de nueve sociedades y expertos invitados)
    Joep Perk · 2012
  73. Addressing Low-Density Lipoprotein (LDL) in Mexican Americans With Diabetes in the NHANES (1999–2000 and 2001–2002)
    Judith Aponte · 2010 · Holistic Nursing Practice
  74. Statins: Risk-Benefits and Role in Treating Dyslipidemias
    Antonio M. Gotto, Jennifer E. Moon · 2015 · Contemporary Endocrinology
  75. Ghidul european de prevenţie a bolilor cardiovasculare în practica clinică (versiunea 2012) Al Cincilea Comitet al Societăţii Europene de Cardiologie şi a altor Societăţi de Prevenţie a Bolilor Cardiovasculare în Practica Clinică (constituit din reprezentanţi ai nouă societăţi şi experţi invitaţi) Dezvoltat cu contribuţia specială a Asociaţiei Europene pentru Prevenţie şi Reabilitare Cardiovasculară (EACPR)
    Joep Perk · 2014
  76. 5. Cardiovascular Diseases
    Hiroto Sone, Nobuhiro Yamada · 2009 · Nihon Naika Gakkai Zasshi
  77. Resumo Pacientes com síndrome metabólica (SM) têm alto risco coronariano e a disfunção da célula beta ou resistência à insulina pode prever um risco adicional de eventos cardiovasculares precoces. Objetivo: Avaliar as alterações glicometabólicas precoces em pacientes com SM, mas sem diagnóstico de diabete tipo
    Carlos M. C. Monteiro, L. M. Oliveira, Maria Cristina de Oliveira Izar, Tatiana Helfenstein, Andreza Oliveira dos Santos, Sahana W. Barros, Luiz Fernando Muniz Pinheiro, Antônio Carlos Carvalho, Francisco Antônio Helfenstein Fonseca · 2009
  78. Diabetes education centre attendance and the effect on medication utilization in the elderly in Ontario
    Cathy M. Murray · 2015 · Memorial University Research Repository (Memorial University)
  79. Use of Cholesterol-Lowering Medications of Patients with Myocardial Infarction from 2007-2015 in Cardiology Clinic to “Mother Teresa” University Hospital in Albania
    Kleva Shpati, Rudina Prifti, Dritan Shpati, Zana Bruci, Erina Hilaj · 2016 · Pharmacology &amp Pharmacy
  80. Effectiveness of Individual-Level Interventions to Prevent Vascular Complications
    Amanda Adler · 2010 · Oxford University Press eBooks
  81. Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes
    Karam Kostner, Stephen James Nicholls, John V. Amerena, Alex D. H. Brown, Mark Emmanuel Cooper, C. Hammett, Richard Charles O’Brien, Leonard Kritharides, David L. Hare, Gerald Francis Watts et al. · 2016 · Heart Lung and Circulation
  82. Improving Target LDL-C Levels in Diabetic Patients Using the Electronic Health Record: Primary Care Practice Improvement Project
    Wendy Gallagher, Alicia Hinton · 2015
  83. Medikamentöse Therapie von Fettstoffwechselstörungen bei Patienten mit Typ-2-Diabetes
    Dirk Müller‐Wieland, Klaus Georg Parhofer · 2018 · Diabetologie und Stoffwechsel
  84. High intensity lipid‐lowering therapy after acute coronary syndromes: room for improvement
    Karam Kostner · 2018 · The Medical Journal of Australia
  85. Medikamentöse Therapie von Fettstoffwechselstörungen bei Patienten mit Typ-2-Diabetes
    Dirk Müller‐Wieland, Klaus Georg Parhofer · 2019 · Gefäßmedizin Scan - Zeitschrift für Angiologie Gefäßchirurgie diagnostische und interventionelle Radiologie
  86. In Stufen zu möglichst niedrigem LDL-Cholesterin bei Diabetes
    Ovidiu Alin Stirban · 2019 · Info Diabetologie
  87. Exploration the Standard diagnosis and treatment in Patients with Type 2 Diabetes in a tertiary first-class hospital in Fujian Province
    Xiaoyan Lin, Wei Lin, Junping Wen, Gang Chen · 2020 · medRxiv
  88. Thérapeutique des désordres associés
    2010 · Elsevier eBooks
  89. Thérapeutique des désordres associés
    2014 · Elsevier eBooks
  90. Non-cardiovascular comorbidities in patients with chronic coronary syndromes (review) (2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes)
    V. P. Lupanov · 2020 · Meditsinskiy sovet = Medical Council
  91. AVALIAÇÃO DAS COMPLICAÇÕES EM PACIENTES COM DIABETES MELLITUS TIPO 1 ATENDIDOS EM UMA CLÍNICA PARTICULAR ESPECIALIZADA E AMBULATÓRIO PÚBLICO DE JOINVILLE - SC
    Lucas Irineu Medeiros de Oliveira, Eloise Mariani Salamaia, Guilherme Thomaz dos Santos, Suely Keiko Kohara · 2021 · Arquivos Catarinenses de Medicina
  92. Efficacy Trials of Sorghum based Composite Flour Mix on the Blood Glucose Levels of Experimental Induced Hyperglycemic Rats
    Manisha Sharma, Mamoni Das, Jadav Sarma, Alam S. · 2021 · The Indian Journal of Nutrition and Dietetics
  93. Residual cardiovascular risk and practical management of type 2 diabetes
    Miles Fisher, Ian W Campbell · 2006 · The British Journal of Diabetes
  94. Bayesian Analysis for Cardiovascular Risk Factors in Ischemic Heart Disease
    Sarada Ghosh, G. P. Samanta, Manuel De la Sen · 2021 · Processes
  95. Optimizing Cardiovascular Outcomes in Patients with Type 2 Diabetes—Clinical Implications of the FIELD Results
    Peter H. Jones · 2006 · US Cardiology Review
  96. Diabetes Mellitus: Alterations in Vessel Wall Properties
    Claudia R.L. Cardoso, Gil Fernando Salles · 2015 · Springer eBooks
  97. Reply
    Kwang Kon Koh, Michael J. Quon · 2010 · Journal of the American College of Cardiology
  98. Compliance with Cardiovascular Prevention Guidelines in Individuals with Type 2 Diabetes in a Middle-Income Region: Cross-Sectional Analysis
    Joaquim Barreto, Beatriz Luchiari, Vaneza Lira Waldow Wolf, Isabella Bonilha, Ticiane Gonçalez Bovi, Barbara Assato, Ikaro Soares Santos Breder, Sheila T. Kimura-Medorima, Daniel Munhoz, Thiago Quinaglia et al. · 2021 · SSRN Electronic Journal
  99. Chapter 1: Introduction
    2007 · European Journal of Cardiovascular Prevention & Rehabilitation
  100. Current literature in diabetes
    2006 · Diabetes/Metabolism Research and Reviews